ArticleSkeletal radiology2026
Primary bone lymphoma: a radiologic-pathologic series of 72 cases uncovering the diagnostic complexity of a rare and heterogeneous entity.
Article in Skeletal radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPrimary bone lymphoma (PBL) is a rare extranodal lymphoma accounting for approximately 7% of malignant primary bone tumors. It typically presents with nonspecific features, frequently resulting in diagnostic delay and inappropriate initial management. MATERIAL AND
methodsWe retrospectively analyzed the characteristics of 72 patients diagnosed with PBL between 1966 and 2025 at a tertiary referral center in Spain.
resultsDiffuse large B-cell lymphoma (DLBCL) was the predominant histological subtype. The most frequent presentations included persistent bone pain, pathological fractures, and palpable masses, often associated with elevated LDH levels or underlying immunosuppressive conditions. Imaging findings were heterogeneous, ranging from permeative lytic patterns to sclerotic lesions, occasionally resembling osteomyelitis or other aggressive neoplasms. MRI proved essential for early detection, accurate assessment of bone marrow infiltration, and soft tissue extension, while CT played a key role in biopsy guidance. FDG PET/CT was critical for staging, restaging, and treatment response evaluation. Diagnostic precision depended heavily on close clinico-radiological-pathological correlation, particularly in cases with atypical or misleading imaging patterns. Most patients were treated with combined chemotherapy and radiotherapy, which was associated with high response rates and favorable survival outcomes.
conclusionPBL is an uncommon but potentially curable malignancy. Early diagnosis requires a high index of suspicion and systematic integration of clinical data, laboratory findings, and multimodal imaging. PBL should be systematically considered in patients presenting with aggressive-appearing bone lesions, pathological fractures, or unexplained marrow replacement, especially in the presence of elevated LDH levels or immunosuppression, in order to prevent diagnostic delay and optimize outcomes.
Indexed as
Identifiers
42542494What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.